AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04411628
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV.
Trial: NCT04607603
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered in capsules of identical appearance to CBD capsules in 3 doses per die
Trial: NCT02844179
Drug: HTBZ
RxNorm normalized name: Hypertebain
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00225303
Drug: TMC125
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00950599
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets, Oral, 0 mg, once daily, 6 and 12 weeks
Trial: NCT03858634
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo dose administered via 2 SC injections within 30 minutes on Day 1. All subsequent doses of placebo administered via a single SC injection.
Trial: NCT03171727
Drug: low molecular weight heparin
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After TIPS procedure was performed, low molecular weight heparin was given for three days.
Trial: NCT01854645
Drug: GP MDI
RxNorm normalized name: carbetapentane citrate / guaifenesin Oral Solution [Pulmari-GP]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GP MDI administered as two puffs BID
Trial: NCT00947518
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cleansing the skin (except the face)with baby wipes containing normal saline
Trial: NCT04130919
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets administered orally once daily
Trial: NCT00700284
Drug: placebo vaginal ring
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vaginal ring containing no TMC120 (dapivirine)
Trial: NCT03826485
Drug: PRIC
RxNorm normalized name: APRICOT
DrugBank: Apricot (DB10502)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pranlukast hydrate 50mg
Trial: NCT02118753
Drug: Eplerenone
RxNorm normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: eplerenone administered ex vivo (to the organ bath in which human atrial tissue is exposed)
Trial: NCT02647554
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo every 8 hours for 10 days
Trial: NCT01427803
Drug: Naproxen Sodium ER (BAYH6689)
RxNorm normalized name: naproxen Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAYH6689; oral tablet used as needed upon incidence of pain
Trial: NCT02777931
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo capsules
Trial: NCT01430104
Drug: Alfarol 1.0 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally throughout the study
Trial: NCT03888716
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 and 100 mg placebo encapsulated tablets
Trial: NCT00662714
Drug: short-acting Insulin (Actrapid)
RxNorm normalized name: Short-acting sulfonamides
FDA approved: no
EMA approved: no
PMDA approved: no
Description: initial dose: 3x 0.05E/kg/d, injected; 2 years
Trial: NCT05288673
Drug: ALXN1210
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALXN1210 was administered by IV infusion over 5 periods, 1 dose per period: Period 1, induction; Periods 2-5, maintenance. Participants received a total of 5 doses of 400 or 800 mg, each administered every 28 days.
Trial: NCT05288673
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo was administered by IV infusion over 5 periods, 1 dose per period. Participants received the same volume and infusion rate as specified for each ALXN1210 dose (400 or 800 mg).
Trial: NCT00807625
Drug: Depo Provera
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Depo Provera administered by injection at randomization visit and the 12-week study visit.
Trial: NCT04140903
Drug: Early transition to oral antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be treated with an oral antibiotic regimen (e.g. amoxicillin + metronidazole) based upon pharmacokinetic and pharmacodynamic properties of the drugs, pathogen susceptibility, and any existing drug allergies or interactions
Trial: NCT04140903
Drug: Standard treatment of intravenous antibiotics
RxNorm normalized name: combinations of different antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will continue standard intravenous antibiotic therapy for brain abscess (e.g. 3rd generation cephalosporin + metronidazole) according to international guidelines and pathogen susceptibility patterns.
Trial: NCT04643470
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match zanubrutinib
Trial: NCT01464983
Drug: Acetylsalicylic acid (Aspirin, BAYE4465)
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid 500 mg orally, single dose, 1 tablet; in addition, 1 Placebo tablet of Acetylsalicylic acid, and 2 Placebo tablets of Ibuprofen
Trial: NCT01464983
Drug: Acetylsalicylic acid (Aspirin, BAYE4465)
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid 2 x 500 mg orally, single dose, 2 tablets; in addition, 2 Placebo tablets of Ibuprofen
Trial: NCT01464983
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen 200 mg orally, single dose, 1 tablet; in addition, 1 Placebo tablet of Ibuprofen, and 2 Placebo tablets of Acetylsalicylic Acid
Trial: NCT01464983
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen 2 x 200 mg orally, single dose, 2 tablets; in addition, 2 Placebo tablets of Acetylsalicylic Acid
Trial: NCT01464983
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 Placebo tablets of Acetylsalicylic Acid, and 2 Placebo tablets of Ibuprofen, orally, single dose
Trial: NCT00354900
Drug: Aprotinin
RxNorm normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03792984
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PO for 8 weeks.
Trial: NCT01162395
Drug: AZD3514
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be given AZD3514 orally as a single dose, and then multiple once daily dosing following a 5-9 day washout.
Trial: NCT02003222
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02003222
Drug: Leucovorin Calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV or PO
Trial: NCT02003222
Drug: Mercaptopurine
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT02003222
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO, IT or IV
Trial: NCT02122471
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02629809
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00124449
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: solution, intravenous injection, 0 mg, monthly, 169 days
Trial: NCT01803477
Drug: once daily for two consecutive days (Picato)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03047954
Drug: Placebo - Cap
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo capsule administered
Trial: NCT04484922
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: continuous infusion of normal saline during the surgery
Trial: NCT01871987
Drug: FK949E
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT02714634
Drug: Methotrexate + targeted therapy administration
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: * Methotrexate or leflunomide + adalimumab or~* Methotrexate or leflunomide + certolizumab or~* Methotrexate or leflunomide + etanercept or~* Methotrexate or leflunomide + golimumab or~* Methotrexate or leflunomide + infliximab or~* Methotrexate or leflunomide + abatacept or~* Methotrexate or leflunomide + rituximab or~* Methotrexate or leflunomide + tocilizumab or~* Methotrexate or leflunomide + sarilumab or~* Methotrexate or leflunomide + filgotinib or~* Methotrexate or leflunomide + upadacitinib or~* Methotrexate or leflunomide + Tofacitinib or~* Methotrexate or leflunomide + baricitinib
Trial: NCT02714634
Drug: methotrexate or leflunomide + sulfasalazine + hydroxychloroquine administration
RxNorm normalized name: Leflunomide
DrugBank: Leflunomide (DB01097)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03111069
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose Escalation: Heated Doxorubicin delivered by Hyperthermic Intraperitoneal Chemotherapy (HIPEC). After abdominal surgery two large bore catheters are placed in the peritoneal cavity through the incision. Starting dose of Doxorubicin is 15 mg/L of HIPEC perfusate.~Dose Expansion Starting Dose: MTD from Dose Escalation.
Trial: NCT02836600
Drug: LY3039478
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT02122731
Drug: Amiloride
RxNorm normalized name: Amiloride
DrugBank: Amiloride (DB00594)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5 mg(daily of amiloride was added to patients triple antihypertensive therapy and increased to 10 mg/daily if office blood pressure at 4 weeks was above 130/80 mmHg.
Trial: NCT03975647
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given twice per day orally
Trial: NCT02770261
Drug: Rosuvastatin 20mg
RxNorm normalized name: ROSUVASTATIN 20MG CAP,SPRINKLE
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: DP-R208 placebo + Candesartan 32mg placebo + Rosuvastatin 20mg
Trial: NCT02770261
Drug: DP-R208 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DP-R208 placebo + Candesartan 32mg placebo + Rosuvastatin 20mg
Trial: NCT02770261
Drug: Rosuvastatin 20mg Placebo
RxNorm normalized name: rosuvastatin 20 MG
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: DP-R208 placebo + Candesartan 32mg + Rosuvastatin 20mg placebo
Trial: NCT02359162
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 mg/m 2 /day 24 h continuous infusion on days 1-4
Trial: NCT02359162
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: cyclophosphamide 750 mg/m2 /day over 15 min intravenously on day 5
Trial: NCT03895359
Drug: Transarterial Chemoembolization
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transarterial chemoembolization is a standard treatment for patients with hepatocellular carcinoma (liver cancer). Chemotherapy is injected into the arteries of the liver and liver cancer.
Trial: NCT02788474
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02236481
Drug: TNF alpha inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01115803
Drug: LY2584702
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplied as 25 milligrams (mg) and 100 mg capsules, administered orally for two 28-day cycles.
Trial: NCT02815488
Drug: Placebo (Part 1 - SAD)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single doses of placebo matching CHF6297 at each period (for up to 3 periods per subject)
Trial: NCT02815488
Drug: Placebo (Part 2 - MAD)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily doses of placebo matching CHF6297 for 7 days
Trial: NCT02815488
Drug: Placebo (Part 3)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily doses of placebo matching CHF6297 for 14 days
Trial: NCT02815488
Drug: Placebo (Part 4)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily doses of placebo matching CHF6297 for 7 days
Trial: NCT02000050
Drug: FOLFOX4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFOX4
Trial: NCT02513563
Drug: AZD1775
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive AZD1775 225 mg twice daily, days 1 and 2 and once a day on day 3 (5 doses) during each 21 day cycle of treatment.
Trial: NCT02631356
Drug: Ringer's lactate solution
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02548468
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04304950
Drug: Morning Group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will take their IBD medication (either azathioprine or 6-mercaptopurine) between 6:00 am and 11:00 am.
Trial: NCT04171388
Drug: Azithromycin 500 mg
RxNorm normalized name: azithromycin 500 MG
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin 500mg (Kern Pharma): 2g (4 tablets) at 2 time points during pregnancy: enrollment (\<=24 weeks gestation), and follow-up ANC at least 4 weeks later
Trial: NCT04171388
Drug: Placebo oral tablet 500 mg
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 500mg (Idifarma): 2g (4 tablets) at 2 time points during pregnancy; enrollment (\<24 weeks gestation), and follow up ANC at least 4 weeks later
Trial: NCT02829983
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Use of 500mg of Clarithromycin twice a day for 3 days
Trial: NCT02829983
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of placebo tablets twice a day for 3 days.
Trial: NCT03178422
Drug: NicoDerm CQ Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine Replacement Therapy
Trial: NCT02874963
Drug: Non Surgical Periodontal Treatment includes post operative mouth wash with Listerine® (ethanol 21.6%, methyl salicylate 0.06%, menthol 0.042%, thymol 0.064% and eucalyptol 0.092%)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Previous to surgery procedures, in particular in the two groups with an adjunctive non surgical periodontal treatment such as full mouth tooth cleaning will be included mouth wash with Listerine® (ethanol 21.6%, methyl salicylate 0.06%, menthol 0.042%, thymol 0.064% and eucalyptol 0.092%) for the 3 weeks after tooth extraction and cleaning.
Trial: NCT04136171
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eplontersen-matching placebo by subcutaneous injection
Trial: NCT03298672
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo solution for subcutaneous injection
Trial: NCT04528628
Drug: SSRIs/SNRIs (Selective Serotonin Reuptake Inhibitors/ Serotonin and Norepinephrine Reuptake Inhibitors)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be treated with one kind of selective serotonin reuptake inhibitors/ serotonin and norepinephrine reuptake inhibitors. Dose is titrated to the minimum effective dose within 2 weeks. Benzodiazepines can be used for a short period lasting no more than 2 weeks.
Trial: NCT04528628
Drug: Treatment as Usual
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The research doctor discusses the treatment plan with the patient, and therapies and drugs are not limited.
Trial: NCT03558997
Drug: Placebo matching SCIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching SCIT was prepared in the same formulation (SCIT diluent) without the addition of Timothy grass extract
Trial: NCT02017171
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive oral tablets identical in appearance to allopurinol tablets.
Trial: NCT03800290
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily ingestion of placebo capsules for a total period of 14 days with a wash-out period of 4 weeks.
Trial: NCT00418665
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects in the control group will receive placebo via subcutaneous injection.
Trial: NCT00345189
Drug: CNF2024
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CNF2024 capsules administered orally following 2 schedules:~* starting dose of 25 mg, twice a week for 3 weeks out of a 4-week course (Schedule 1) or~* starting dose of 600 mg twice a week for 4 weeks out of a 4-week course (without drug holidays; Schedule 2).~Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. Dose escalation proceeds according to the predetermined scheme until the stopping dose is reached due to a dose limiting toxicity (DLT) occurring during the first 4-week course of treatment.
Trial: NCT04485273
Drug: Local Anesthetic Solution and Dexmedetomedine
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The local anesthetic solution is injected with a dose of 0.5% bupivacaine (0.08 ml/kg), in addition to dexmedetomedine (0.5 μg /kg)
Trial: NCT04485273
Drug: Local Anesthetic Solution
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The local anesthetic solution is injected with a dose of 0.5% bupivacaine (0.08 ml/kg).
Trial: NCT00071266
Drug: Niacin Extended Release and Lovastatin Tablets
RxNorm normalized name: lovastatin / niacin Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00079014
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT03783702
Drug: Ibuprofen 600 Mg (milligram) Oral Tablet
RxNorm normalized name: ibuprofen 600 MG
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients in the experimental group will receive ibuprofen 600mg as the second-line analgesic.
Trial: NCT03783702
Drug: Acetaminophen 650 MG (milligram) Oral Tablet
RxNorm normalized name: acetaminophen 650 MG
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients will receive acetaminophen as the first-line analgesic.
Trial: NCT02198339
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02056405
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 pill of the same characteristics as Mosapride every 8 hs with 30 ml tap water. This will begin on postoperative day 1 until discharge from Hospital or unacceptable toxicity develops.
Trial: NCT00931385
Drug: bi1744
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1744 low dose
Trial: NCT00931385
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Respimat and Foradil Placebo
Trial: NCT02778763
Drug: CBLB612
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 μg CBLB612 SQ
Trial: NCT02778763
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02296125
Drug: AZD9291 80 mg/40 mg + placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The initial dose of AZD9291 80 mg once daily can be reduced to 40 mg once daily under specific circumstances. A cycle of treatment is defined as 21 days of once daily treatment.~Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
Trial: NCT00469261
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxycycline 100 mg bid for seven days after enrollment
Trial: NCT00469261
Drug: Current medical therapy for AMI
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current medical therapy for AMI
Trial: NCT01064245
Drug: high-dose methacholine challenge test
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nebulized liquid inhalation, 0.0625 - 256 mg/mL, doubling doses
Trial: NCT02360657
Drug: JNJ-54861911, 10 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-54861911, 10 mg (2\*5 mg tablet) orally once daily for 4 weeks.
Trial: NCT02360657
Drug: JNJ-54861911, 50 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-54861911, 50 mg (2\*25 mg tablet) orally once daily for 4 weeks.
Trial: NCT02360657
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching to JNJ-54861911 tablet orally once daily for 4 weeks.
Trial: NCT02431481
Drug: LEE011
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg
Trial: NCT00066807
Drug: chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Planned duration of chemotherapy: 2 months if an anthracycline is included (e.g., 4 cycles of EC or AC) or 4 months if no anthracycline is given (e.g., 6 cycles of CMF) is recommended. Unless medically contraindicated, an anthracycline-containing regimen using epirubicin should be given.
Trial: NCT02123628
Drug: duration of the antibiotic therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01418729
Drug: Pravastatin
RxNorm normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment:~Patients will be randomized in two groups, A and B:~* Control Group (A ≡ 1): Patients will receive treatment with sorafenib 400 mg/12 h + placebo/24 h.~* Experimental Group (B ≡ 2): The treatment received will be sorafenib 400 mg/12 h + pravastatin 40 mg/24 h.